REGN
Price
$617.00
Change
-$17.23 (-2.72%)
Updated
Apr 1 closing price
Capitalization
67.45B
27 days until earnings call
VRTX
Price
$484.74
Change
-$0.08 (-0.02%)
Updated
Apr 1 closing price
Capitalization
124.48B
28 days until earnings call
Ad is loading...

REGN vs VRTX

Header iconREGN vs VRTX Comparison
Open Charts REGN vs VRTXBanner chart's image
Regeneron Pharmaceuticals
Price$617.00
Change-$17.23 (-2.72%)
Volume$1.06M
Capitalization67.45B
Vertex Pharmaceuticals
Price$484.74
Change-$0.08 (-0.02%)
Volume$1.25M
Capitalization124.48B
REGN vs VRTX Comparison Chart
Loading...
REGN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VRTX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
REGN vs. VRTX commentary
Apr 02, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is REGN is a Hold and VRTX is a StrongBuy.

Ad is loading...
COMPARISON
Comparison
Apr 02, 2025
Stock price -- (REGN: $634.23 vs. VRTX: $484.74)
Brand notoriety: REGN: Notable vs. VRTX: Not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: REGN: 113% vs. VRTX: 87%
Market capitalization -- REGN: $67.45B vs. VRTX: $124.48B
REGN [@Biotechnology] is valued at $67.45B. VRTX’s [@Biotechnology] market capitalization is $124.48B. The market cap for tickers in the [@Biotechnology] industry ranges from $302.51B to $0. The average market capitalization across the [@Biotechnology] industry is $2.22B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

REGN’s FA Score shows that 1 FA rating(s) are green whileVRTX’s FA Score has 3 green FA rating(s).

  • REGN’s FA Score: 1 green, 4 red.
  • VRTX’s FA Score: 3 green, 2 red.
According to our system of comparison, VRTX is a better buy in the long-term than REGN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

REGN’s TA Score shows that 3 TA indicator(s) are bullish while VRTX’s TA Score has 5 bullish TA indicator(s).

  • REGN’s TA Score: 3 bullish, 6 bearish.
  • VRTX’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, VRTX is a better buy in the short-term than REGN.

Price Growth

REGN (@Biotechnology) experienced а -4.05% price change this week, while VRTX (@Biotechnology) price change was -4.77% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -9.07%. For the same industry, the average monthly price growth was -13.26%, and the average quarterly price growth was -12.25%.

Reported Earning Dates

REGN is expected to report earnings on Apr 29, 2025.

VRTX is expected to report earnings on Apr 30, 2025.

Industries' Descriptions

@Biotechnology (-9.07% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
VRTX($124B) has a higher market cap than REGN($67.5B). VRTX has higher P/E ratio than REGN: VRTX (32.76) vs REGN (16.09). VRTX YTD gains are higher at: 20.372 vs. REGN (-10.850). REGN has higher annual earnings (EBITDA): 5.32B vs. VRTX (486M). REGN has more cash in the bank: 9.01B vs. VRTX (6.12B). VRTX has less debt than REGN: VRTX (1.75B) vs REGN (2.7B). REGN has higher revenues than VRTX: REGN (14.2B) vs VRTX (11B).
REGNVRTXREGN / VRTX
Capitalization67.5B124B54%
EBITDA5.32B486M1,094%
Gain YTD-10.85020.372-53%
P/E Ratio16.0932.7649%
Revenue14.2B11B129%
Total Cash9.01B6.12B147%
Total Debt2.7B1.75B155%
FUNDAMENTALS RATINGS
REGN vs VRTX: Fundamental Ratings
REGN
VRTX
OUTLOOK RATING
1..100
6383
VALUATION
overvalued / fair valued / undervalued
1..100
3
Undervalued
78
Overvalued
PROFIT vs RISK RATING
1..100
7314
SMR RATING
1..100
5491
PRICE GROWTH RATING
1..100
6422
P/E GROWTH RATING
1..100
8928
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

REGN's Valuation (3) in the Biotechnology industry is significantly better than the same rating for VRTX (78). This means that REGN’s stock grew significantly faster than VRTX’s over the last 12 months.

VRTX's Profit vs Risk Rating (14) in the Biotechnology industry is somewhat better than the same rating for REGN (73). This means that VRTX’s stock grew somewhat faster than REGN’s over the last 12 months.

REGN's SMR Rating (54) in the Biotechnology industry is somewhat better than the same rating for VRTX (91). This means that REGN’s stock grew somewhat faster than VRTX’s over the last 12 months.

VRTX's Price Growth Rating (22) in the Biotechnology industry is somewhat better than the same rating for REGN (64). This means that VRTX’s stock grew somewhat faster than REGN’s over the last 12 months.

VRTX's P/E Growth Rating (28) in the Biotechnology industry is somewhat better than the same rating for REGN (89). This means that VRTX’s stock grew somewhat faster than REGN’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
REGNVRTX
RSI
ODDS (%)
N/A
Bearish Trend 2 days ago
54%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
70%
Bullish Trend 2 days ago
73%
Momentum
ODDS (%)
Bearish Trend 2 days ago
61%
Bearish Trend 2 days ago
43%
MACD
ODDS (%)
Bearish Trend 2 days ago
60%
Bearish Trend 2 days ago
46%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
56%
Bearish Trend 2 days ago
44%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
64%
Bullish Trend 2 days ago
63%
Advances
ODDS (%)
Bullish Trend 23 days ago
61%
Bullish Trend 16 days ago
61%
Declines
ODDS (%)
Bearish Trend 12 days ago
52%
Bearish Trend 2 days ago
43%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
45%
Bullish Trend 2 days ago
72%
Aroon
ODDS (%)
Bullish Trend 2 days ago
62%
Bullish Trend 2 days ago
62%
View a ticker or compare two or three
Ad is loading...
REGN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VRTX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
MSEX64.100.62
+0.98%
Middlesex Water Company
PINE16.720.11
+0.66%
Alpine Income Property Trust
WRB71.16-0.11
-0.15%
WR Berkley Corp
CNX31.48-0.15
-0.47%
CNX Resources Corp
PAVM0.72-0.03
-3.81%
PAVmed